profit from every $100 of sales.
$0$100
Bio-Rad Laboratories
$370.48-4.02% today
+13.2% in 1 year
1-year low $241.711-year high $390.34
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $13.11 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bio-Rad Laboratories sold, what it kept, and what it did with the cash.
Sales went from $2.80 billion in 2022 to $2.58 billion in 2025, with $760 million of profit last year.
SalesProfit
Bio-Rad Laboratories handed back 79% of the cash it generated last year.
Buybacks $296M
Free cash flow 2025$375M
Bought back its own shares$296M
Paid as dividends–
Cash vs. debt$530M vs. $1.4B
Bio-Rad Laboratories vs. similar companies
Bio-Rad Laboratories grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bio-Rad Laboratories | 13.1× · Cheap | ||
 Abbott Laboratories | 28.5× · Fair price | ||
 Medtronic | 26.9× · Fair price | ||
 Stryker | 36.6× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Bio-Rad Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,546 | 2,923 | 2,802 | 2,671 | 2,567 | 2,583 | |
| 1,438 | 1,638 | 1,567 | 1,427 | 1,379 | 1,340 | |
| 421 | 500 | 475 | 338 | 269 | 219 | |
| 5,078 | 5,588 | -4,529 | -655 | -2,142 | 1,210 | |
| 3,814 | 4,254 | -3,628 | -637 | -1,844 | 760 | |
| 126.47 | 140.83 | -121.79 | -21.82 | -65.36 | 27.85 | |
| 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% | |
| 16.6% | 17.1% | 17.0% | 12.6% | 10.5% | 8.5% | |
| 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 12,973 | 17,799 | 13,502 | 12,299 | 9,364 | 10,577 |
| Cash | 662 | 471 | 434 | 404 | 488 | 530 |
| Total debt | 224 | 223 | 1,388 | 1,406 | 1,375 | 1,386 |
| Total liabilities | 3,093 | 4,114 | 3,886 | 3,558 | 2,795 | 3,123 |
| 9,890 | 13,685 | 9,615 | 8,741 | 6,569 | 7,454 | |
| 30 | 30 | 30 | 29 | 28 | 27 | |
| 38.6% | 31.0% | -33.5% | -6.2% | -22.8% | 9.3% | |
| 38.6% | 31.1% | -37.7% | -7.3% | -28.1% | 10.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 585 | 669 | 194 | 375 | 455 | 532 | |
| 109 | 134 | 114 | 157 | 189 | 158 | |
| 476 | 536 | 80 | 218 | 266 | 375 | |
| Dividends paid | – | – | – | – | – | – |
| 100 | 50 | 216 | 429 | 204 | 296 | |
| 42 | 51 | 61 | 61 | 62 | 58 |
Valuation
- 13.1×
- 40.4×
- –
- 1.3×
- 3.9×
- 26.6×
- 8.9×
- 3.8%
- 7.6%
- 0.0%
Profitability
- 51.9%
- 8.5%
- 29.4%
- 1.3%
- 9.6%
- -13.6%
- 2.4%
- 1.7%
- 2.7%
- 10.1%
Growth
- +0.3%
- −26.1%
- +40.7%
- –
- −2.9%
Financial health
- 0.7×
- 0.19
- 14.1%
- 21.3×
- 5.62
- 3.21
- 0.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 32%of 952
Bottom 48%of 883
Top 17%of 576
Bottom 16%of 870
Top 29%of 985
What analysts expect
- Average price target
- $312.50
- Range
- $290.00 – $335.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.89 | 1.99 | −5.0% |
| Feb 12, 2026 | 2.51 | 2.57 | −2.3% |
| Oct 29, 2025 | 2.26 | 2.30 | −1.7% |
| Jul 31, 2025 | 2.61 | 1.93 | +35.2% |
| May 1, 2025 | 2.54 | 1.73 | +46.8% |
| Feb 13, 2025 | 2.90 | 2.86 | +1.4% |
| Oct 30, 2024 | 2.01 | 1.28 | +57.0% |
| Aug 1, 2024 | 3.11 | 2.12 | +46.7% |
News
Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17Seeking Alpha · Nov 12, 2026MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stockSeeking Alpha · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
72Pass
Philip Fisher
46No pass
Peter Lynch
32No pass
Joel Greenblatt
48No pass
Charlie Munger
50No pass
Terry Smith
34No pass
Questions about Bio-Rad Laboratories
Is Bio-Rad Laboratories a good stock to buy?
A strong, very profitable business, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bio-Rad Laboratories AI analysis
What does Bio-Rad Laboratories do?
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. It is in Medical Devices, based in Hercules, CA, United States, with 7,450 employees.
Does Bio-Rad Laboratories pay a dividend?
No. Bio-Rad Laboratories does not pay a dividend at the moment; in 2025 it returned $296 million to shareholders by buying back its own shares.
Is Bio-Rad Laboratories stock halal?
Yes. Bio-Rad Laboratories passes our halal screen: its business is permitted and its debt is 14% of its market value, under the 30% limit. How we check
How has Bio-Rad Laboratories stock done over the past year?
Up 13.2% over the past twelve months, to $370.48. It traded between $241.71 and $390.34 and is 5.1% below its high.
Who are Bio-Rad Laboratories's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Bio-Rad Laboratories's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.